Effective September 11, 2009, the FDA granted approval for Vibativ, an injectable lipoglycopeptide antibiotic for the treatment of adult patients with complicated skin and skin structure infections caused by susceptible Gram-positive bacteria, including methicillin-resistant (MRSA) and methicillin-susceptible (MSSA) strains of Staphylococcus Aureus.
According to the package insert, Vibativ should be infused intravenously over a 60-minute period, once daily for seven to 14 days. The recommended dose for patients over 18 years of age is 10mg/kg.
Submit the following codes for Vibativ services:
- CPT code 96365 – Intravenous infusion for therapy, prophylaxis or diagnosis up to one hour
- HCPCS code J3490 – unclassified drugs for the Vibativ injection
- Enter the following information in Loop 2300 or 2400, NTE, 02 (for paper claims, submit NDC information on an attachment to the claim form):
- NDC number
- Vibativ
- Dose given
- Until Palmetto GBA receives sufficient claims to determine a price, providers must submit an invoice copy for this drug
NOTE: This drug is supplied in 250 mg and 750 mg single-dose vials. Providers should use the appropriate vial(s) to minimize waste.